Monoclonal Antibody Treatment for COVID-19 at Rutland Regional
From the emergency department to the intensive care unit (ICU), the healthcare providers at Rutland Regional Medical Center provide evidence-based treatment for patients and community members with COVID-19.
In addition to providing emergency and inpatient care for COVID-19, Rutland Regional has received a supply of monoclonal antibody medications that can be given as an outpatient intravenous (IV) infusion. Monoclonal antibodies are used to treat mild to moderate cases of COVID-19 in individuals who are at a high risk of developing severe COVID-19 complications that may require hospitalization.
What are monoclonal antibodies?
Monoclonal antibodies are proteins that are made in the lab and mimic the immune system’s ability to combat viruses and other infection-causing antigens.
Casirivimab/imdevimab, commonly known as “the Regeneron cocktail,” as well as bamlanivimab, are investigational monoclonal antibody therapies that received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration.
How does monoclonal antibody therapy work?
Monoclonal antibody therapy works by blocking the COVID-19 virus from entering human cells and causing infection. When administered within 10 days of COVID-19 symptom onset in patients with mild-to-moderate symptoms, monoclonal antibody therapy has been shown to prevent symptoms from progressing and lowers the risk of hospitalization.
Who is eligible for monoclonal antibody therapy?
Non-hospitalized adult and pediatric patients ages 12 and older with a positive COVID test and mild-to-moderate symptoms who are at high risk of progressing to severe COVID-19 and/or hospitalization are eligible for monoclonal antibody therapy.
Monoclonal antibody therapy must be given via outpatient infusion as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. Hospitalized patients are not eligible for monoclonal antibody therapy.
“High-risk” is defined as patients who meet at least one of the following criteria:
- Have a body mass index (BMI) ≥ 35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥ 65 years of age
- Are ≥ 55 years of age AND have:
- Cardiovascular disease, OR
- Hypertension, OR
- Chronic obstructive pulmonary disease/other chronic respiratory disease
- Are 12-17 years of age AND have
- BMI ≥ 85th percentile for their age and gender based on CDC growth charts, OR
- Sickle cell disease, OR
- Congenital or acquired heart disease, OR
- Neurodevelopmental disorders, for example, cerebral palsy, OR
- A medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
- Asthma, reactive airway, or other chronic respiratory disease that requires daily medication for control
How is monoclonal antibody therapy administered?
Monoclonal antibody therapy is administered via intravenous (IV) infusion only. The medication must be administered in a setting where healthcare providers have immediate access to medications to treat infusion reactions such as anaphylaxis, and provide emergency treatment if necessary.
Where can I find additional information about monoclonal antibody therapy?
Please review the Fact Sheet for Patients, Parents, and Caregivers for additional information. You can also speak to your healthcare provider if you have additional questions or concerns.
What should you do if you think you or a loved one may qualify for monoclonal antibody therapy?
If you or your loved one has a positive COVID-19 test, are experiencing COVID-19 symptoms, and believe you may qualify for monoclonal antibody therapy, contact your healthcare provider right away.